$SMMT CRL as we predicted and the reason for it is why we stayed out.
“The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement.”
@Veekay0606@EastsideDrexrp Yeah could be as simple as a delay. Share price would definitely drop whether it’s a CRL or delay.
$CYTK has no decision out yet which, in my opinion, gives $SMMT holders more hope that they could actually get positive news Monday.
I had $CYTK at about 90% POA
$INO was a risky one, but with how beaten down it was - I should’ve taken a small stake in it. Wound up taking a quick flip on it after news came out of approval. If $INO had gotten a CRL I wouldn’t expect it to have dropped a crazy amount from where it already was. $SMMT is a different story though
@EastsideDrexrp Yeah I had about 90% chance of approval, but didn’t expect much of a move from them.
I will say, not hearing any news on either of them is encouraging for $SMMT
I only flipped this one for profits. Holding through the decision is too risky based on missing the OS endpoint.
My “rulebook” for PDUFA’s is that if we don’t get news by about 6 pm EST, we assume bad news. Typically, when there’s a PDUFA on the weekend, you’ll get the news the Friday before. These are a couple reasons why I expect Monday news will release of a CRL. $SMMT
For those holding, I hope my strategy is wrong this time, but most of the time that’s how it works out.
Close tape ⚡️
$XBI $150.55 (-0.4%), bought back from a $148.17 low
$CADL $6.20 (-26%) on the BLA slip to mid-2027
$PEPG $4.36 (-13.5%), back under the $5.00 raise
$IONS $29.06 (+6.4%) off the 52-wk low
$SLS $7.86, faded from $9.00
Early tape ⚡️
$CADL $6.27 (-25%), opened $5.20 on the BLA slip to mid-2027
$SLS $8.20 (+2.1%), tagged $9.00, REGAL topline due this month
$XBI $149.24 (-1.3%)
PDUFA clock:
$SMMT $14.31, Sat Nov 14
$SVRA $4.73, Nov 22
$PYPD $6.16, Nov 28
$COGT $28.75, Nov 30
NFA
Last session before Saturday's $SMMT PDUFA ⚡️
$14.23 (-5.6%), was $17.84 three sessions ago. OS HR 0.76, nominal p=0.0151. FDA asked for stat-sig OS.
52-wk low $12.07.
Weekend headline, Monday gap.
NFA
@BioStocks $KYTX tagged $6.41 premarket on the headline and is already back to $5.05 (-1.5%).
If FDA grants priority, that's an 8-month clock from submission. Stock sits about 55 cents off its $4.50 52-wk low.
$SMMT 2 days to the PDUFA
FDA told them it wanted stat-sig OS. HARMONi missed it.
September analysis: nominally significant OS in the global population.
CCO seat empty since August.
$15.88, down 4.6% today. 52-wk range $12.07 to $29.23.
Saturday decision = Monday gap either way.
Early tape ⚡️
$XBI $153.62 (-1.7%)
$ADXN $4.62 (+60%), tagged $6.50
$KYTX $5.05 (-1.5%), faded the BLA pop
$VNDA $4.13 (-0.6%)
PDUFA clock:
$SMMT $15.88, Sat Nov 14
$SVRA $4.82, Nov 22
$CAPR $10.77, Nov 22 (Sun, Fri 20th in play)
$COGT $29.60, Nov 30
NFA
$PEPG priced the $125M raise at $5.00 ⚡️
25M shares + 3.75M option, closes Nov 13.
Priced 4.9% under the $5.26 close. Trading $5.35 premarket, above the deal.
Cash was $104.8M at Sep 30 before this. Last raise was $100M at $3.20 in Sep 2025.
DM1 runway just got a lot longer.
$CAPR
Thin evidence: the arm win rests on a single trial with p=0.029. That's significant, but not by a wide margin, and the FDA usually wants either two trials or one very strong one.
Open inspection finding: the July FDA inspection of the clinical trial sites left one finding that Capricor has answered but the FDA hasn't closed. Findings at trial sites go to whether the data can be trusted, so this one matters more than a typical plant-inspection note.
History: there's a prior rejection, and it's a cell therapy, where manufacturing reviews are tough. Narrowing the label in the middle of a review can also read as the company retreating to the claim it can defend.